Pancreatic Cancer Research

ResearcherThe University of Texas Southwestern Medical CenterActive in the last 2 years

Huocong Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6345-4566; OpenAlex author ID A5060384080. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
49
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 3 papers

Papers 18

  1. Paracrine regulation of pancreatic cancer cell response to chemotherapy by GLI2-collagen I signaling. Co-author DOI 10.1016/j.jbc.2025.110311↗
  2. A spatial atlas of chemoradiation therapy in pancreatic cancer identifies cellular and microenvironmental determinants of persister populations Co-author DOI 10.1101/2025.06.20.660757↗
  3. SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. Co-author DOI 10.1158/0008-5472.can-24-1970↗
  4. Diagnostic and Prognostic Markers for Pancreatitis and Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms25126619↗
  5. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.04.011↗
  6. AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-21-0293↗
  7. Targeting TNF-α-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling. Co-author DOI 10.1172/jci.insight.153242↗
  8. AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0860↗
  9. DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. Co-author DOI 10.1172/jci.insight.146133↗
  10. Beyond Stiffness: Collagen Signaling in Pancreatic Cancer and Pancreas Regeneration. Co-author DOI 10.1016/j.ajpath.2020.05.005↗
  11. Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. Co-author DOI 10.1038/s41598-020-77373-8↗
  12. Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1152/ajpcell.00079.2020↗
  13. The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-3751↗
  14. Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Prec… Co-author DOI 10.1158/1541-7786.mcr-18-0427↗
  15. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. First author DOI 10.1172/jci.insight.129212↗
  16. Targeting TGFβR2-mutant tumors exposes vulnerabilities to stromal TGFβ blockade in pancreatic cancer. Co-author DOI 10.15252/emmm.201910515↗
  17. Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1158/1535-7163.mct-16-0834↗
  18. Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1. Co-author DOI 10.1074/jbc.m116.740605↗

Closest collaborators

The 25 strongest of 49 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rolf A. Brekken · 16 shared papers, 2017–2025 · strength 2.42
  2. Thomas Martin Wilkie · 3 shared papers, 2020–2024 · strength 0.39
  3. Jason B. Fleming · 3 shared papers, 2017–2025 · strength 0.38
  4. Eugene Jon Koay · 3 shared papers, 2019–2025 · strength 0.37
  5. Wenting Du · 4 shared papers, 2017–2021 · strength 0.36
  6. Yuqing Zhang · 3 shared papers, 2019–2022 · strength 0.35
  7. Gilbert Zvikomborero Murimwa · 2 shared papers, 2022–2025 · strength 0.34
  8. Matthew H. G. Katz · 2 shared papers, 2021–2025 · strength 0.29
  9. Anirban Maitra · 2 shared papers, 2019–2025 · strength 0.27
  10. Yalda Zolghadri · 2 shared papers, 2020–2024 · strength 0.26
  11. Havish Sairaju Kantheti · 2 shared papers, 2020–2024 · strength 0.26
  12. Renzo Emanuel Vera · 1 shared paper, 2025 · strength 0.22
  13. Ezequiel J. Tolosa · 1 shared paper, 2025 · strength 0.22
  14. Martín E. Fernández-Zapico · 1 shared paper, 2025 · strength 0.22
  15. Cecilia Grace Ethun · 1 shared paper, 2025 · strength 0.20
  16. Aatur Dilip Singhi · 1 shared paper, 2025 · strength 0.20
  17. Albert C. Koong · 1 shared paper, 2025 · strength 0.17
  18. Daniela Tovar · 1 shared paper, 2025 · strength 0.17
  19. Tianyu Wang · 1 shared paper, 2025 · strength 0.17
  20. Jimin Min · 1 shared paper, 2025 · strength 0.17
  21. Robert A. Wolff · 1 shared paper, 2025 · strength 0.17
  22. Vincent Bernard · 1 shared paper, 2025 · strength 0.17
  23. Guangsheng Pei · 1 shared paper, 2025 · strength 0.17
  24. Ethan Bernard Ludmir · 1 shared paper, 2025 · strength 0.17
  25. Manoop S. Bhutani · 1 shared paper, 2025 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.